EGFR and neoplasm: The findings illustrated that risk score performed better in contrast with tumor grade, gender, age, LGG diagnosis type, tumor type (recurrent and primary), as well as mutation status of IDH1 (R132), ATRX, EGFR, TP53, and PTEN, along with some other factors (Figures 8C–E).